Citalopram: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Citalopram. Educational only — not medical advice.

Reported adverse reactions

ReactionHighest frequency reported*
Sweating increased11%
Tremor8%
Diarrhea8%
Ejaculation disorder6%
Dyspepsia5%
Fatigue5%
Upper respiratory tract infection5%
Rhinitis5%
Nausea4%
Anxiety4%
Anorexia4%
Insomnia3%
Abdominal pain3%
Dysmenorrhea3%
Sinusitis3%
Impotence3%
Dizziness2%
Somnolence2%
Fever2%
Arthralgia2%

*Highest percentage across placebo-controlled trial tables summarized in current labeling.

Labeled uses

Citalopram HBr, USP is indicated for the treatment of depression. The efficacy of Citalopram tablets, USP in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-lll and DSM-lll-R category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The antidepressant action of Citalopram tablets, USP in hospitalized depressed patients has not been adequately studied. The efficacy of Citalopram tablets, USP in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controll…

Source: FDA labeling via NIH DailyMed (set c8b0a9d1…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.